



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/208,195	12/09/1998	JAN E. SCHNITZER	BIDMC98-20	7811

21005 7590 04/08/2002
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
530 VIRGINIA ROAD
P.O. BOX 9133
CONCORD, MA 01742-9133

[REDACTED] EXAMINER

NOLAN, PATRICK J

ART UNIT	PAPER NUMBER
1644	[REDACTED]

DATE MAILED: 04/08/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/208,195	Applicant(s) Schnitzer et al.
	Examiner Patrick J. Nolan	Art Unit 1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on Jan 9, 2002

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. '11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-9, 11-17, 19-22, 24, 25, and 27-30 is/are pending in the application.

4a) Of the above, claim(s) 27-30 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-9, 11-17, 19-22, 24, and 25 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are objected to by the Examiner.

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a) All b) Some* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). _____

16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152)

17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) Other: _____

Serial Number: 09/208,195

Art Unit: 1644

Part III DETAILED ACTION

Claims 1-9, 11-17, 19-22, 24-25 and 27-30 are pending.

1. Claims 1-9, 11-17, 19-22, 24-25 and 27-30 are pending.

2. Claims 27-30 stand withdrawn from consideration as being directed to a non-elected invention, for reasons set forth in Paper No. 14.

3. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6-8-01 has been entered.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 1-9, 11-17, 19-22 and 24-25 stand rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for isolating caveolae by using antibody which binds oligomerized caveolin in its native state as an oligomeric structural cage surrounding intact caveolae, wherein said monoclonal antibody is CAV or otherwise known as Mab clone 2234, does not reasonably provide enablement for the use of any monoclonal antibody which binds oligomerized caveolin in its native state as an oligomeric structural cage surrounding intact caveolae. The specification does not enable any person skilled in the art to which it pertains, or with which it is most clearly connected, to use the invention commensurate in scope with these claims, for reasons set forth in Paper No. 20.

Applicant's arguments filed 1-9-02 have been fully considered but are not found persuasive.

Applicant argues that one of skill in the art could easily screen for additional antibodies which have the properties of Applicant's CAV monoclonal antibody.

However, the state of the art and Applicant's own specification teaches that additional experimentation has already been done to identify additional monoclonal antibodies with the same properties as the CAV monoclonal antibody disclosed, and they have failed. Since the state of the art teaches unpredictability in being able to create additional antibodies with the properties of

Serial Number: 09/208,195
Art Unit: 1644

Applicant's sole monoclonal antibody CAV, it would require an undue amount of experimentation to practice the full scope of Applicant's claimed invention.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --
(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. Claims 1-4, 6, 11 and 14 stand rejected under 35 U.S.C. § 102(b) as being anticipated by Scherer et al. (U), of record for reasons set forth in Paper No. 20.

Applicant's arguments set forth in Paper No. 21 have been fully considered but are not found persuasive.

Applicant argues that immunoisolation is different from immunoprecipitation, therefore the prior art does not read on the claimed invention.

This argument is not found persuasive because Attorney's arguments are not considered evidence where evidence is required. (MPEP 2145).

If applicant can demonstrate by a State of the art reference or by a declaration that the prior art immunoprecipitation method taught by Scherer et al., would not result in intact caveolae, the Examiner will reconsider.

6. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for response to this final action is set to expire THREE MONTHS from the date of this action. In the event a first response is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for response expire later than SIX MONTHS from the date of this final action.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is (703) 305-1987. The examiner can normally be reached on Monday through Friday from 8:30 am to 4:30

Serial Number: 09/208,195

Art Unit: 1644

pm.

8. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at (703) 305-3973. The FAX number for our group, 1644, is (703) 305-7939. Any inquiry of a general nature relating to the status of this application or proceeding should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Pat J. Nolan

Patrick J. Nolan, Ph.D.
Primary Examiner, Group 1640
April 7, 2002